TBK1/NAK Antibody [C14L9] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Lane 1: Raji

Usage Information

Dilution
WB1:1000 IP1:100 IF1:200-1:800 FCM1:1600-1:3200

Application
WB, IP, IF, FCM

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
84 kDa

Datasheet & SDS

Biological Description

Specificity
TBK1/NAK Antibody [C14L9] detects endogenous levels of total TBK1/NAK protein.

Clone
C14L9

Synonym(s)
Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1; TBK1; NAK

Background
TBK1 (TANK-binding kinase 1, NAK), a serine/threonine kinase of the IKK-related family alongside IKKε, integrates diverse innate immune signals as a central hub converging cytosolic DNA/RNA sensing with inflammatory transcription across myeloid cells, fibroblasts, and epithelial barriers. It features an N-terminal kinase domain, central scaffold/dimerization region, and C-terminal ubiquitin-binding TBK1/IKKi coiled-coil domain that licenses trans-autophosphorylation at Ser172 upon recruitment to adaptors like STING, MAVS, or TRIF. Ligand-induced clustering, such as cyclic dinucleotides binding STING—recruits TBK1 dimers via specific pLxIS motifs, triggering K48/K63-linked polyubiquitination that relieves autoinhibition and enables sequential phosphorylation of IRF3/7 at multiple serines for dimerization, nuclear translocation, and type I interferon induction; parallel IKK complex activation via NEMO/RelA sustains NF-κB-driven cytokine production while TBK1 phosphorylates STAT6 for chemokine expression and OPTN for selective autophagy of cytosolic pathogens. This dual output coordinates immediate antiviral states with adaptive recruitment, as TBK1 phosphorylates p62 for aggresome clearance and mTORC1 components to balance metabolic reprogramming during infection. TBK1 orchestrates antiviral defense in dendritic cells, limits immunopathology through negative feedback via TANK/Optineurin sequestration, and maintains barrier integrity in lung epithelia, making it the preferred readout for researchers assaying cytosolic sensing fidelity via phospho-IRF3 westerns or CRISPR organoids challenged with cGAMP. Loss-of-function mutations cause hereditary spirochetosis and immunodeficiency, while somatic amplification drives KRAS-mutant lung cancer survival through YAP/TEAD non-canonical signaling.

Background

TBK1 (TANK-binding kinase 1, NAK), a serine/threonine kinase of the IKK-related family alongside IKKε, integrates diverse innate immune signals as a central hub converging cytosolic DNA/RNA sensing with inflammatory transcription across myeloid cells, fibroblasts, and epithelial barriers. It features an N-terminal kinase domain, central scaffold/dimerization region, and C-terminal ubiquitin-binding TBK1/IKKi coiled-coil domain that licenses trans-autophosphorylation at Ser172 upon recruitment to adaptors like STING, MAVS, or TRIF. Ligand-induced clustering, such as cyclic dinucleotides binding STING—recruits TBK1 dimers via specific pLxIS motifs, triggering K48/K63-linked polyubiquitination that relieves autoinhibition and enables sequential phosphorylation of IRF3/7 at multiple serines for dimerization, nuclear translocation, and type I interferon induction; parallel IKK complex activation via NEMO/RelA sustains NF-κB-driven cytokine production while TBK1 phosphorylates STAT6 for chemokine expression and OPTN for selective autophagy of cytosolic pathogens. This dual output coordinates immediate antiviral states with adaptive recruitment, as TBK1 phosphorylates p62 for aggresome clearance and mTORC1 components to balance metabolic reprogramming during infection. TBK1 orchestrates antiviral defense in dendritic cells, limits immunopathology through negative feedback via TANK/Optineurin sequestration, and maintains barrier integrity in lung epithelia, making it the preferred readout for researchers assaying cytosolic sensing fidelity via phospho-IRF3 westerns or CRISPR organoids challenged with cGAMP. Loss-of-function mutations cause hereditary spirochetosis and immunodeficiency, while somatic amplification drives KRAS-mutant lung cancer survival through YAP/TEAD non-canonical signaling.

References
https://pubmed.ncbi.nlm.nih.gov/35395857/ https://pubmed.ncbi.nlm.nih.gov/33785602/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%